References
- Nicholson B . Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain . Pain Pract.9 ( 1 ), 71 – 81 ( 2009 ).
- Webster L . Update on abuse-resistant and abuse-deterrent approaches to opioid formulations . Pain Med.10 ( Suppl. 2 ), S124 – S133 ( 2009 ).
- Butler SF , BlackRA , FlemingAB . Relative abuse of crush-resistant prescription opioid tablets via alternative oral modes of administration . Pain Med.http://doi.org/10.1093/pm/pnx151 ( 2017 ) ( Epub ahead of print ).
- Moorman-Li R , MotyckaCA , IngeLD , CongdonJM , HobsonS , PokropskiB . A review of abuse-deterrent opioids for chronic nonmalignant pain . PT37 ( 7 ), 412 – 418 ( 2012 ).
- Pergolizzi JV Jr , TaylorRJr , NalamachuSet al. Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives . Curr. Med. Res. Opin.30 ( 2 ), 191 – 202 ( 2014 ).
- Hale ME , MoeD , BondM , GasiorM , MalamutR . Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain . Pain Manag.6 ( 5 ), 497 – 508 ( 2016 ).
- Butler SF , CassidyTA , ChilcoatHet al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment . J. Pain14 ( 4 ), 351 – 358 ( 2013 ).
- Kopecky EA , FlemingAB , NoonanPKet al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx(R): an extended-release, abuse-deterrent formulation . J. Opioid Manag.10 ( 4 ), 233 – 246 ( 2014 ).
- Fleming AB , ScungioTA , GrimaMP , MayockSP . In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx(R) microspheres . J. Opioid Manag.12 ( 1 ), 57 – 65 ( 2016 ).
- Gudin J , Levy-CoopermanN , KopeckyEA , FlemingAB . Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties . Pain Med.16 ( 11 ), 2142 – 2151 ( 2015 ).
- McCarberg BH , KopeckyEA , O’ConnorMet al. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia . Curr. Med. Res. Opin.32 ( 12 ), 1975 – 1982 ( 2016 ).
- Food and Drug Administration . Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies . CDER , MD, USA ( 2002 ).
- Kopecky EA , FlemingAB , Levy-CoopermanN , O’ConnorM , SellersEM . Oral human abuse potential of oxycodone DETERx® (Xtampza® ER) . J. Clin. Pharmacol.57 ( 4 ), 500 – 512 ( 2017 ).
- Harris S , ColucciS , PerrinoP , MandarinoD . Effects of various tampering methods on exposure to oxycodone in healthy subjects. Poster No. 78 . Presented at : The 74th Annual Scientific Meeting on the College on Problems of Drug Dependence . CA, USA , 9–14 June 2012 .
- Center for Behavior Health Statistics and Quality . Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Serioes H-50) ( 2015 ) www.samhsa.gov/data/sites/default/files/NSDUH-FRR1–2014/NSDUH-FRR1–2014.pdf .
- Severtson SG , EllisMS , KurtzSPet al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone . Drug Alcohol Depend.168 , 219 – 229 ( 2016 ).
- McNaughton EC , CoplanPM , BlackRA , WeberSE , ChilcoatHD , ButlerSF . Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse . J. Med. Internet Res.16 ( 5 ), e119 ( 2014 ).
- Katz N , DartRC , BaileyE , TrudeauJ , OsgoodE , PaillardF . Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions . Am. J. Drug Alcohol Abuse37 ( 4 ), 205 – 217 ( 2011 ).
- OxyContin®, package insert . Purdue Pharma L.P. , CT, USA ( 2015 ). http://app.purduepharma.com/xmlpublishing/pi.aspx?id=o .
- Kadian® ER, package insert . Actavis Pharma, Inc. , NJ, USA ( 2014 ). www.allergan.com/assets/pdf/kadian_pi .
- Opana® ER, package insert . Endo Pharmaceuticals, Inc. , PA, USA ( 2014 ). www.endo.com/File%20Library/Products/Prescribing%20Information/OpanaER_prescribing_information_newformulation.html .
- MS Contin®, package insert . Purdue Pharma L.P. , CT, USA ( 2014 ). http://app.purduepharma.com/xmlpublishing/pi.aspx?id=ms .
- Exalgo®, package insert . Mallinckrodt Brand Pharmaceuticals, Inc. , MO, USA ( 2014 ). www2.mallinckrodt.com/workarea/downloadasset.aspx?id=2147483728 .
- Zohydro®, package insert . Pernix Therapeutics, LLC. , NJ, USA ( 2016 ). www.zohydroer.com/downloads/ZOHYDROERFullPrescribingInformation.pdf .
- Hysingla®, package insert . Purdue Pharma L.P. , CT, USA ( 2015 ). http://app.purduepharma.com/xmlpublishing/pi.aspx?id=h .
- Xtampza® ER, package insert . Collegium Pharmaceutical, Inc. , MA, USA ( 2016 ). www.xtampzaer.com/pdf/xtampza-pi.pdf .
- Vowles KE , McEnteeML , JulnesPS , FroheT , NeyJP , van der GoesDN . Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis . Pain156 ( 4 ), 569 – 576 ( 2015 ).
- Food and Drug Administration . CDER guidance for industry: abuse-deterrent opioids – evaluation and labeling . MD, USA ( 2015 ). www.fda.gov/downloads/Drugs/Guidances/UMC334743.pdf .
- Kopecky EA , FlemingAB , Levy-CoopermanN , O’ConnorM , SellersE . Oral human abuse potential of oxycodone DETERx® (Xtampza® ER) . J. Clin. Pharmacol.57 , 500 – 512 ( 2017 ).
- Webster LR , KopeckyEA , SmithMD , FlemingAB . A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone . Pain Med.17 ( 6 ), 1112 – 1130 ( 2016 ).